Immucell reports preliminary Q2 revenue $7.2M
"Total sales for the three months ended June 30, 2026 were $7.2 million, an 11.5% increase compared to the three months ended June 30, 2025, driven by a 27.7% increase in domestic sales compared to 2025," said Timothy Fiori, CFO of ImmuCell. "Our growth in the second quarter is particularly significant given the challenging comparison with the second quarter of 2025, when ImmuCell recorded substantial sales from distributors replenishing inventory following an extended period of backorders. International sales in the three months ended June 30, 2026 declined $0.6 million, or 38.9% compared to 2025; however, we believe that end-customer demand remains strong, particularly in Canada. Total sales for the six months ended June 30, 2026 were $17.5 million, a 20.9% increase compared to the six months ended June 30, 2025."
"Total sales for the three months ended June 30, 2026 were $7.2 million, an 11.5% increase compared to the three months ended June 30, 2025, driven by a 27.7% increase in domestic sales compared to 2025," said Timothy Fiori, CFO of ImmuCell. "Our growth in the second quarter is particularly significant given the challenging comparison with the second quarter of 2025, when ImmuCell recorded substantial sales from distributors replenishing inventory following an extended period of backorders.
International sales in the three months ended June 30, 2026 declined $0.6 million, or 38.9% compared to 2025; however, we believe that end-customer demand remains strong, particularly in Canada.
Total sales for the six months ended June 30, 2026 were $17.5 million, a 20.9% increase compared to the six months ended June 30, 2025."